Literature DB >> 9973194

Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins.

H Dotzlaw1, E Leygue, P H Watson, L C Murphy.   

Abstract

When the level of estrogen receptor (ER)-beta mRNA in tumors, determined by reverse transcription-PCR, was assessed according to either ER status or PR status alone, determined by ligand binding assays, the level of ER-beta mRNA was significantly lower in PR+ tumors compared with PR- tumors (P = 0.036), and no association with ER status was found. Subgroup analysis showed that ER-beta mRNA expression in ER+/PR+ breast tumors was significantly less than in ER+/PR- (P = 0.009), ER-/PR+ (P = 0.029), and ER-/PR- (P = 0.023) groups. Interestingly, the ER-beta mRNA expression was specifically decreased by progestin in T47D breast cancer cells. The data suggest the possibility that expression of ER-beta in human breast tumors is a marker of endocrine therapy responsiveness.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9973194

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  26 in total

1.  Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways.

Authors:  Xiaodong Li; Jing Huang; Ping Yi; Robert A Bambara; Russell Hilf; Mesut Muyan
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 2.  The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.

Authors:  D A Tonetti; V C Jordan
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

3.  Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland.

Authors:  Paola Mussi; Lan Liao; Seong-Eun Park; Paolo Ciana; Adriana Maggi; Benita S Katzenellenbogen; Jianming Xu; Bert W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-25       Impact factor: 11.205

4.  Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.

Authors:  T A Järvinen; M Pelto-Huikko; K Holli; J Isola
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

5.  Estrogen receptors alpha and beta in the rodent mammary gland.

Authors:  S Saji; E V Jensen; S Nilsson; T Rylander; M Warner; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

6.  Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells.

Authors:  Yun Teng; Tissa T Manavalan; Chuan Hu; Svjetlana Medjakovic; Alois Jungbauer; Carolyn M Klinge
Journal:  Toxicol Sci       Date:  2012-10-10       Impact factor: 4.849

7.  Estrogen receptors and proliferation markers in primary and recurrent breast cancer.

Authors:  E V Jensen; G Cheng; C Palmieri; S Saji; S Mäkelä; S Van Noorden; T Wahlström; M Warner; R C Coombes; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

Review 8.  The normal and malignant mammary gland: a fresh look with ER beta onboard.

Authors:  M Warner; S Saji; J A Gustafsson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

9.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

10.  Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.

Authors:  Bhuvaneswari Ramaswamy; Sarmila Majumder; Satavisha Roy; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Mamoun Younes; Charles L Shapiro; Tasneem Motiwala; Samson T Jacob
Journal:  Mol Endocrinol       Date:  2008-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.